Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which inhibits the protective functions of anti-tumor immunity and thereby contributes to PDAC progression. Recently, the study of Alam et al. discovered for the first time that the intratumoral fungal mycobiome could contribute to the recruitment and activation of type 2 immune cells in the TME of PDAC via enhancing the secretion of a chemoattractant, interleukin (IL-) 33. In this article, we reviewed the important findings of this study. Together with our findings, we synthetically discussed the role of the fungal mycobiome in orchestrating the immune response and thereby modulating tumor progression.

Keywords

Mycobiome / pancreatic cancer / chemoresistance / interleukin 33 / type 2 immune cells

References

[1] Cui L,Ghedin E.The human mycobiome in health and disease.Genome Med2013;5:63 PMCID:PMC3978422

[2] Seed PC.The human mycobiome.Cold Spring Harb Perspect Med2014;5:a019810 PMCID:PMC4448585

[3] Vallianou N,Christodoulatos GS,Karampela I.Mycobiome and cancer: what is the evidence?.Cancers2021;13:3149 PMCID:PMC8269322

[4] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[5] Giovannetti E,Frampton AE,Firuzi O.Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer.Semin Cancer Biol2017;44:43-59

[6] Aykut B,Chen R.The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL.Nature2019;574:264-7 PMCID:PMC6858566

[7] Wang H,Krom BP,Giovannetti E.Of fungi and men: role of fungi in pancreatic cancer carcinogenesis.Ann Transl Med2020;8:1257 PMCID:PMC7607088

[8] Clark CE,Mick R,Tuveson DA.Dynamics of the immune reaction to pancreatic cancer from inception to invasion.Cancer Res2007;67:9518-27

[9] Dey P,Zhang J.Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment.Cancer Discov2020;10:608-25

[10] Alam A,Denz P.Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.Cancer Cell2022;40:153-167.e11 PMCID:PMC8847236

[11] Liew FY,Turnquist HR.Interleukin-33 in health and disease.Nat Rev Immunol2016;16:676-89

[12] Dunkelberger JR.Complement and its role in innate and adaptive immune responses.Cell Res2010;20:34-50

[13] Schmitz J,Oldham E.IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.Immunity2005;23:479-90

[14] Hodzic Z,Bolock AM.IL-33 and the intestine: the good, the bad, and the inflammatory.Cytokine2017;100:1-10 PMCID:PMC5650929

[15] Moussion C,Girard JP.The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”?.PLoS One2008;3:e3331 PMCID:PMC2556082

[16] Pichery M,Mercier P.Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.J Immunol2012;188:3488-95

[17] Carriere V,Ortega N.IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.Proc Natl Acad Sci U S A2007;104:282-7 PMCID:PMC1765450

[18] Martin NT.Interleukin 33 is a guardian of barriers and a local alarmin.Nat Immunol2016;17:122-31

[19] Malik A,Zhu Q.IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis.J Clin Invest2016;126:4469-81 PMCID:PMC5127671

[20] Sesti-Costa R,Proença-Módena JL.The IL-33/ST2 pathway controls coxsackievirus B5-induced experimental pancreatitis.J Immunol2013;191:283-92

[21] Kobori A,Imaeda H.Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis.J Gastroenterol2010;45:999-1007

[22] Jiang Y,Jiang D,Yang Y.TNF-α regulating interleukin-33 induces acute pancreatic inflammation in rats.Ann Clin Lab Sci2016;46:54-9

[23] Moral JA,Rojas LA.ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.Nature2020;579:130-5 PMCID:PMC7060130

[24] Giovannetti E,Avan A.Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.J Natl Cancer Inst2014;106:djt346 PMCID:PMC3906994

[25] Zeng Q,Chryplewicz A et al.Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.Science2022;378:eabl7207

[26] Choy ATF,Coppola S.The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.Expert Rev Mol Diagn2018;18:1005-9

[27] Geller LT,Danino T.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.Science2017;357:1156-60

[28] Pushalkar S,Daley D.The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression.Cancer Discov2018;8:403-16 PMCID:PMC6225783

[29] Riquelme E,Zhang L.Tumor microbiome diversity and composition influence pancreatic cancer outcomes.Cell2019;178:795-806.e12 PMCID:PMC7288240

[30] Lefrançais E.Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members.Eur Cytokine Netw2012;23:120-7

[31] Ghalamfarsa G,Raoofi Mohseni S.CD73 as a potential opportunity for cancer immunotherapy.Expert Opin Ther Targets2019;23:127-42

[32] Moesta AK,Smyth MJ.Targeting CD39 in cancer.Nat Rev Immunol2020;20:739-55

[33] Yoshikawa T,Kamata K,Minaga K.Intestinal dysbiosis and autoimmune pancreatitis.Front Immunol2021;12:621532 PMCID:PMC8021793

[34] Satoh-Takayama N,Motomura Y.Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA.Immunity2020;52:635-649.e4

[35] Robinson KM,Clay ME,Rich HE.Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection.Mucosal Immunol2018;11:199-208 PMCID:PMC5638662

[36] Bukavina L,Isali I.Human gut mycobiome and fungal community interaction: the unknown musketeer in the chemotherapy response status in bladder cancer.Eur Urol Open Sci2022;43:5-13 PMCID:PMC9638757

[37] Kudo-Saito C,Imazeki H,Aoki K.IL33 is a key driver of treatment resistance of cancer.Cancer Res2020;80:1981-90

[38] Xuan B,Cheney EM,Dawson MR.Dysregulation in actin cytoskeletal organization drives increased stiffness and migratory persistence in polyploidal giant cancer cells.Sci Rep2018;8:11935 PMCID:PMC6085392